Outset Medical, Inc. (OM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '21: 91.7M Q4 '21: 102.6M Q1 '22: 110.2M Q2 '22: 110.1M Q3 '22: 111.5M Q4 '22: 115.4M Q1 '23: 118.3M Q2 '23: 129.3M Q3 '23: 131.9M Q4 '23: 130.4M Q1 '24: 125.1M Q2 '24: 116.4M Q3 '24: 114.7M Q4 '24: 113.7M Q1 '25: 115.3M Q2 '25: 119.3M Q3 '25: 120.1M Q4 '25: 119.5M Q1 '26: 117.6M Q2 '26: 117.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 20M 40M 60M Q3 '21: 4.7M Q4 '21: 7.6M Q1 '22: 11.8M Q2 '22: 14.5M Q3 '22: 15.9M Q4 '22: 17.8M Q1 '23: 19.8M Q2 '23: 23.7M Q3 '23: 26.6M Q4 '23: 29M Q1 '24: 30.8M Q2 '24: 32.9M Q3 '24: 35.5M Q4 '24: 38.6M Q1 '25: 41.4M Q2 '25: 43.5M Q3 '25: 45.3M Q4 '25: 46.8M Q1 '26: 47.8M Q2 '26: 49.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -121.3M Q4 '21: -130.5M Q1 '22: -137.3M Q2 '22: -151.1M Q3 '22: -162M Q4 '22: -161M Q1 '23: -168M Q2 '23: -167.8M Q3 '23: -172.2M Q4 '23: -169.8M Q1 '24: -163.2M Q2 '24: -150.5M Q3 '24: -128.9M Q4 '24: -113.4M Q1 '25: -92.9M Q2 '25: -79M Q3 '25: -70.9M Q4 '25: -66.7M Q1 '26: -67.2M Q2 '26: -66M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -122.7M Q4 '21: -131.9M Q1 '22: -138.8M Q2 '22: -152.4M Q3 '22: -162.7M Q4 '22: -163M Q1 '23: -170M Q2 '23: -170.2M Q3 '23: -175.6M Q4 '23: -172.8M Q1 '24: -168.8M Q2 '24: -159.2M Q3 '24: -140.9M Q4 '24: -128M Q1 '25: -113.8M Q2 '25: -97.9M Q3 '25: -87.8M Q4 '25: -81.7M Q1 '26: -74.8M Q2 '26: -74.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 40M 80M 120M Q3 '21: 87M Q4 '21: 95M Q1 '22: 98.5M Q2 '22: 95.6M Q3 '22: 95.6M Q4 '22: 97.5M Q1 '23: 98.5M Q2 '23: 105.5M Q3 '23: 105.3M Q4 '23: 101.4M Q1 '24: 94.3M Q2 '24: 83.6M Q3 '24: 79.2M Q4 '24: 75.1M Q1 '25: 73.9M Q2 '25: 75.8M Q3 '25: 74.8M Q4 '25: 72.7M Q1 '26: 69.8M Q2 '26: 68.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -123.4M Q4 '21: -130.3M Q1 '22: -130M Q2 '22: -137.7M Q3 '22: -143.9M Q4 '22: -145.7M Q1 '23: -152.2M Q2 '23: -141.8M Q3 '23: -141.4M Q4 '23: -131.4M Q1 '24: -132.5M Q2 '24: -137.7M Q3 '24: -124.3M Q4 '24: -116.3M Q1 '25: -96.1M Q2 '25: -67.5M Q3 '25: -53.3M Q4 '25: -46.3M Q1 '26: -33.5M Q2 '26: -38.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -128.3M Q4 '21: -133.4M Q1 '22: -133.7M Q2 '22: -142.5M Q3 '22: -151M Q4 '22: -154.1M Q1 '23: -159.8M Q2 '23: -148.2M Q3 '23: -145.9M Q4 '23: -134.8M Q1 '24: -135.5M Q2 '24: -140M Q3 '24: -126.2M Q4 '24: -117.2M Q1 '25: -96.7M Q2 '25: -68.4M Q3 '25: -53.9M Q4 '25: -47.1M Q1 '26: -34.2M Q2 '26: -38.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 5.6M Q1 '21: 42.8M Q2 '21: 45.7K Q3 '21: 46.6K Q1 '22: 47.5K Q2 '22: 47.9K Q3 '22: 48.1K Q1 '23: 48.8K Q2 '23: 49K Q3 '23: 49.9K Q1 '24: 3.4K Q2 '24: 3.5K Q3 '24: 3.5K Q1 '25: 7K Q2 '25: 17.7K Q3 '25: 17.8K Q1 '26: 18.4K Q2 '26: 18.6K Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-105.00 -70.00 -35.00 0.00 35.00 70.00 105.00 Q4 '19: -89.38 Q1 '21: -9.47 Q4 '19 Q1 '21

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.